Biomarkers for cancer therapy
AssigneeThe Council of the Queensland Institute of Medical Research
InventorsJason Lee, Fares Al-Ejeh
Life of this patent
Estimating the term…
Abstract
This invention relates generally to biomarkers that are useful for determining whether a subject with cancer is likely to respond to cancer therapy. The invention therefore relates to methods, kits and compositions for determining whether a subject is likely to respond to cancer therapy, and to methods of treatment based on a determination that a subject with cancer is likely to respond to cancer therapy. The invention also relates to methods for sensitizing a subject with cancer to cancer therapy.
Claims5
A method for determining an indicator used in assessing a likelihood of a subject with cancer responding to cancer therapy, the method comprising, consisting or consisting essentially of:
- (1) determining a biomarker value for at least one cancer therapy biomarker in a sample from the subject, wherein the, or one of the, cancer therapy biomarker(s) is an expression product of MAP1LC3B;
- and
- (2) determining the indicator using the biomarker value(s), wherein the indicator is at least partially indicative of the likelihood of responsiveness to cancer therapy;
- wherein the cancer therapy comprises therapy with an immune checkpoint inhibitor.
-43. (canceled)
A composition for determining an indicator used in assessing a likelihood of a subject with cancer responding to cancer therapy, the composition or solid support comprising, consisting, or consisting essentially of a MAP1LC3B transcript or cDNA thereof and at least one oligonucleotide primer or probe that hybridizes to the MAP1LC3B transcript or cDNA thereof, and an EHMT2 or EHMT1 transcript or cDNA thereof and at least one oligonucleotide primer or probe that hybridizes to the EHMT2 or EHMT1 transcript or cDNA thereof, wherein the cancer therapy comprises therapy with an immune checkpoint inhibitor.
A solid support for determining an indicator used in assessing a likelihood of a subject with cancer responding to cancer therapy, the solid support comprising, consisting, or consisting essentially of at least one first oligonucleotide primer or probe immobilized to the solid support, wherein the at least one first oligonucleotide primer or probe hybridizes to a MAP1LC3B transcript or cDNA;
- and at least one second oligonucleotide primer or probe immobilized to the solid support, wherein the at least one second oligonucleotide primer or probe hybridizes to a EHMT2 or EHMT1 transcript or cDNA thereof, wherein the cancer therapy comprises therapy with an immune checkpoint inhibitor.
-52. (canceled)
Dependencies are inferred from the claim text.